Marietta Wealth Management LLC lifted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.6% during the fourth quarter, Holdings Channel.com reports. The firm owned 11,321 shares of the medical research company’s stock after acquiring an additional 285 shares during the quarter. Thermo Fisher Scientific makes up 1.5% of Marietta Wealth Management LLC’s investment portfolio, making the stock its 23rd biggest holding. Marietta Wealth Management LLC’s holdings in Thermo Fisher Scientific were worth $5,273,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in TMO. Alps Advisors Inc. raised its stake in Thermo Fisher Scientific by 287,808.7% during the third quarter. Alps Advisors Inc. now owns 1,954,900 shares of the medical research company’s stock worth $1,634,000 after buying an additional 1,954,221 shares during the last quarter. FMR LLC increased its stake in Thermo Fisher Scientific by 5.6% in the fourth quarter. FMR LLC now owns 13,022,987 shares of the medical research company’s stock valued at $6,065,847,000 after purchasing an additional 686,768 shares in the last quarter. Sustainable Growth Advisers LP bought a new stake in Thermo Fisher Scientific in the third quarter valued at $280,017,000. BlackRock Inc. increased its stake in Thermo Fisher Scientific by 2.2% in the fourth quarter. BlackRock Inc. now owns 29,504,221 shares of the medical research company’s stock valued at $13,742,475,000 after purchasing an additional 624,512 shares in the last quarter. Finally, AKO Capital LLP bought a new stake in Thermo Fisher Scientific in the third quarter valued at $192,228,000. 87.17% of the stock is owned by institutional investors and hedge funds.
Thermo Fisher Scientific stock traded down $9.78 during midday trading on Tuesday, hitting $453.50. 19,303 shares of the stock were exchanged, compared to its average volume of 1,767,478. Thermo Fisher Scientific Inc. has a 52-week low of $250.21 and a 52-week high of $532.57. The stock has a market capitalization of $179.74 billion, a price-to-earnings ratio of 37.97, a price-to-earnings-growth ratio of 1.40 and a beta of 0.85. The business’s 50-day moving average price is $500.86 and its 200-day moving average price is $464.08. The company has a quick ratio of 2.31, a current ratio of 2.93 and a debt-to-equity ratio of 0.66.
Thermo Fisher Scientific declared that its board has authorized a share buyback plan on Thursday, November 5th that authorizes the company to repurchase $2.50 billion in outstanding shares. This repurchase authorization authorizes the medical research company to repurchase up to 1.2% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s leadership believes its shares are undervalued.
Several equities research analysts have weighed in on the stock. Morgan Stanley lifted their price target on shares of Thermo Fisher Scientific from $535.00 to $575.00 and gave the company an “overweight” rating in a research note on Tuesday, February 2nd. BTIG Research lifted their price target on shares of Thermo Fisher Scientific from $540.00 to $590.00 and gave the company a “buy” rating in a research note on Wednesday, February 3rd. Citigroup lifted their price target on shares of Thermo Fisher Scientific from $500.00 to $530.00 and gave the company a “buy” rating in a research note on Tuesday, February 2nd. Smith Barney Citigroup downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “neutral” rating in a research note on Wednesday, December 16th. Finally, The Goldman Sachs Group started coverage on shares of Thermo Fisher Scientific in a research note on Wednesday, December 2nd. They issued a “buy” rating and a $570.00 price target for the company. Five research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $527.47.
In related news, COO Mark Stevenson sold 14,133 shares of the business’s stock in a transaction dated Monday, December 7th. The shares were sold at an average price of $473.84, for a total transaction of $6,696,780.72. Following the transaction, the chief operating officer now directly owns 58,005 shares in the company, valued at $27,485,089.20. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.44% of the stock is currently owned by insiders.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery and production of drugs and vaccines, and diagnosis of diseases to pharmaceutical, biotechnology, agricultural, clinical, academic, and government markets.
Recommended Story: What is the Gross Domestic Product (GDP)?
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.